Pomelo Capital’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

Pomelo Capital’s Portfolio CELGZ Stock Details CELGZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-15,000	Closed	-$51K	–	103
2014 Q3	$51K	Hold	15,000	–	–	0.03%	70
2014 Q2	$39K	Hold	15,000	–	–	0.02%	76
2014 Q1	$42K	Hold	15,000	–	–	0.02%	68
2013 Q4	$41K	Sell	15,000 -158,954	-91%	-$446K	0.02%	57
2013 Q3	$1.4M	Buy	173,954 +55,204	+46%	+$425K	0.53%	24
2013 Q2	$868K	Buy	+118,750	New	+$861K	0.33%	43

Other funds holding CELGZ

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

FCG Advisors Chatham, New Jersey $425M AUM 12.09% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pomelo Capital's CELGZ Position: Q4 2014 in Review

Pomelo Capital sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q4 2014, closing a stake of 15,000 shares — an estimated $51K sold.

Pomelo Capital first reported a position in CELGZ in Q2 2013 and held it in 6 quarters. The position peaked at $1.4M in Q3 2013. 23 funds tracked by Wall St. Rank hold CELGZ as of Q4 2014.

Pomelo Capital reported no remaining Celgene Corporation Contingent Value Rights position as of Q4 2014 after selling out during the quarter.
Pomelo Capital sold 15,000 Celgene Corporation Contingent Value Rights shares in Q4 2014, an estimated $51K.
Pomelo Capital first reported a position in Celgene Corporation Contingent Value Rights in Q2 2013 and held it in 6 quarters.
Pomelo Capital's Celgene Corporation Contingent Value Rights position peaked at $1.4M in Q3 2013.
23 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q4 2014.

Based on Pomelo Capital's 13F filing for Q4 2014, filed 13 Feb 2015.